Hedge fund Third Point LLC recently pushed $810 million market cap Ligand Pharmaceuticals Inc. into exploring strategic options. Ligand publicized the start of its strategic review and its hiring of UBS on Nov. 18.
To read the entire story, you must be logged in.
Please log in now or register with us.
